5 Takeaways After Fed. Circ. Amgen-Sandoz Ruling
By Jeff Overley ( July 21, 2015, 10:09 PM EDT) -- The Federal Circuit's first interpretation of key provisions in the Biologics Price Competition and Innovation Act contained vague statements that clouded the ruling's impact on biosimilars and featured stark divisions that raised the odds of review by the full court. Here are five issues attorneys should watch in the aftermath of Amgen Inc. v. Sandoz Inc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.